Factors Associated with Persistence with Teriparatide Therapy : Results from the DANCE Observational Study

Abstract EN

Purpose.

Determine patient-reported reasons for discontinuation with teriparatide.

Methods.

Patients taking teriparatide in a multicenter, prospective, and observational study were given three questionnaires: baseline, follow-up questionnaire 1 (QF1, 2 to 6 months), and follow-up questionnaire 2 (QF2, 12 months).

Discontinuation reported at QF1 and QF2 was defined as “early” and “late,” respectively, and remaining patients were considered persistent.

Cochran-Armitage trend test was used to identify factors associated with discontinuation.

Results.

Side effects, concern about improper use, injection difficulties, and several patient-perceived physician issues were associated with early discontinuation.

Low patient-perceived importance of continuing treatment, side effects, difficulty paying, and low patient-perceived physician knowledge were associated with late discontinuation.

The most common specific reasons selected for discontinuing treatment were “concerns about treatment outweighing the benefits” (n=53) and “difficulty paying” (n=47).

Conclusions.

Persistence with teriparatide is dependent on managing side effects, addressing financial challenges, proper training, and obtaining support from the healthcare provider.